Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
16
12
2021
accepted:
07
06
2022
revised:
25
05
2022
pubmed:
26
6
2022
medline:
9
9
2022
entrez:
25
6
2022
Statut:
ppublish
Résumé
ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT) can be complicated by poor red cell engraftment and hemolysis, both mediated by isoagglutinins. Anecdotally, isoagglutinins indicates an activation of donor's immunity or even relapse. Consequently, the routine monitoring of isoagglutinins could help physicians to predict the risk of complications. The purpose of this study is to investigate the time to disappearance and appearance of isoagglutinins after ABO-incompatible allogeneic HSCT. In a one-year follow-up, data of 136 ABO-incompatible hematopoietic stem cell (HSC) allogeneic transplanted patients were studied, of which 60 had major, 61 minor and 15 bidirectional incompatibility. Survival analyses were conducted and association with hematological diseases, HLA-compatibility and transplantation strategy was investigated. We observed a disappearance of isoagglutinin A in 82.0% of cases at one year with a median and 75th percentile of 38.4 and 138.6 days, respectively. For isoagglutinin B, these same values were 96.4%, 15.9 and 29.1 days, respectively. The appearance of isoagglutinin A occurred in 10.7% of cases. Disappearance of isoagglutinin A was significantly slower in patients with myeloid diseases compared to other diseases. The results of this study provide useful values to detect early risks of preventable immunohematological complications and possibly, in exceptional cases, relapse.
Identifiants
pubmed: 35752741
doi: 10.1038/s41409-022-01737-z
pii: 10.1038/s41409-022-01737-z
pmc: PMC9439946
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1405-1410Informations de copyright
© 2022. The Author(s).
Références
Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS, et al. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transpl. 2005;35:489–95.
doi: 10.1038/sj.bmt.1704816
Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. Immunohematology. 2009;25:48–59.
doi: 10.21307/immunohematology-2019-231
Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood.2001;98:1687–94.
doi: 10.1182/blood.V98.6.1687
Rowley S. Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transpl. 2001;28:315–21.
doi: 10.1038/sj.bmt.1703135
Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160:798–805.
doi: 10.1111/bjh.12210
Moosavi MM, Duncan A, Stowell SR, Roback JD, Sullivan HC. Passenger lymphocyte syndrome; a review of the diagnosis, treatment, and proposed detection protocol. Transfus Med Rev. 2020;34:178–87.
doi: 10.1016/j.tmrv.2020.06.004
Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother. 2016;43:3–12.
doi: 10.1159/000441507
Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1152–8.
doi: 10.1016/j.bbmt.2013.03.018
Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol. 2021;8:e229–e39.
doi: 10.1016/S2352-3026(20)30404-X
Chung HJ, Lee JH, Kwon SW. Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation. J Clin Lab Anal. 2008;22:383–90.
doi: 10.1002/jcla.20269
Tajima K, Takizawa K, Yasuda T, Tsumanuma R, Okuyama S, Kumagai H, et al. Characterization of reemergent anti-B red blood cell antibodies in a patient with recurrent acute myeloid leukemia with ABO-incompatible allogeneic peripheral blood stem cell transplantation. Transfusion.2019;59:3319–23.
doi: 10.1111/trf.15510
Copelan E. Hematopoietic stem cell transplantation. N. Engl J Med. 2006;354:1813–26.
doi: 10.1056/NEJMra052638
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood.2014;124:344–53.
doi: 10.1182/blood-2014-02-514778
Lee J-H, Lee J-H, Choi S-J, Kim S, Seol M, Kwon S-W, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol. 2003;120:702–10.
doi: 10.1046/j.1365-2141.2003.04128.x
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. Available from: https://www.R-project.org/ .
Therneau T A Package for Survival Analysis in R. R package version 3.2-11 2021. Available from: https://CRAN.R-project.org/package=survival .
Anderson-Bergman C icenReg: Regression Models for Interval Censored Data in R. Journal of Statistical Software. 2017;81.
Volken T, Crawford RJ, Amar S, Mosimann E, Tschaggelar A, Taleghani BM. Blood Group Distribution in Switzerland - a Historical Comparison. Transfus Med Hemother. 2017;44:210–6.
doi: 10.1159/000479191
Griffith LM, McCoy JP Jr, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128:668–75.
doi: 10.1111/j.1365-2141.2005.05364.x
Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion. 1998;38:975–88.
doi: 10.1046/j.1537-2995.1998.381098440863.x
Lee J-H, Lee K-H, Kim S, Lee J-S, Kim S-H, Kwon S-W, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transpl. 2000;25:179–84.
doi: 10.1038/sj.bmt.1702121
Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651–64.
doi: 10.1038/s41409-021-01227-8
Wernet D, Mayer G. Isoagglutinins following ABO-incompatible bone marrow transplantation. Vox Sang. 1992;62:176–9.
pubmed: 1609520
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200–e12.
doi: 10.1016/S1473-3099(18)30600-5
Laurencet FM, Samii K, Bressoud A, Tajeddin M, Easton J, Stelling MJ, et al. Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Hematol Cell Ther. 1997;39:159–62.
doi: 10.1007/s00282-997-0159-4